Targeted Therapies in Chronic Myeloid Leukemia

Elias Jabbour, Jorge Cortes

Research output: Chapter in Book/Report/Conference proceedingChapter


Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with the interaction between the BCR-ABL protein and adenosine triphosphate (ATP), blocking cellular proliferation of the malignant clone. Three TKIs are commercially available for the front-line treatment of CML: imatinib, dasatinib, and nilotinib. With the updates of the DASISION and ENESTnd trials, the question often arises as to the optimal choice for front-line management of CP-CML. Based on attainment of faster and higher rates of complete cytogenetic response (CCyR), major molecular response (MMR), and complete molecular response (CMR), and a trend for lower progression rates to accelerated phase (AP) or breakpoint cluster, it is reasonable to use a second generation TKI for front-line management.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
Number of pages10
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
StatePublished - Oct 30 2015
Externally publishedYes


  • CML frontline treatment
  • Chronic myeloid leukemia
  • Complete cytogenetic response
  • Complete molecular response
  • Dasatinib
  • Imatinib
  • Major molecular response
  • Nilotinib
  • Small-molecule tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Targeted Therapies in Chronic Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this